FDA grants breakthrough status to Alkermes’ alixorexton for narcolepsy type 1
Alkermes (NASDAQ:ALKS) announced on January 6, 2026, that the U.S. FDA has granted Breakthrough Therapy Designation to alixorexton (formerly ALKS 2680) for the treatment of narcolepsy type 1 (NT1).











